{
    "cancer_info": {
        "cancer_name": "Pediatric Central Nervous System Cancers"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Brain and spine MRI with IV contrast (T1/T2-weighted, FLAIR, DWI, SWI/GRE, post-contrast 3D T1)",
            "CT scan (only if MRI contraindicated)",
            "Histopathological examination with molecular profiling (NGS, methylation arrays)",
            "IHC markers: BRAF V600E, H3 K27me3, IDH1 R132H, INI1/SMARCB1",
            "CSF analysis (lumbar puncture >10 days post-op for cytology)",
            "Biopsy (for atypical lesions or unresectable tumors)",
            "MR perfusion (DSC/DCE/ASL)",
            "MR spectroscopy",
            "PET (FDG) for recurrence vs. radiation necrosis differentiation",
            "Postoperative MRI within 24-48 hours",
            "Germline testing for cancer predisposition syndromes"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Pediatric Diffuse High-Grade Gliomas (pHGG): Location (pontine vs. non-pontine), H3 K27 status, resection extent",
            "risk_group": "Age ≥3 years, non-pontine",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Radiation + Temozolomide",
                    "plan_details": "Radiation Therapy (50.4–54 Gy) with concurrent temozolomide → adjuvant temozolomide ± lomustine",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard regimen"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "BRAF V600E-mutated",
                    "plan_name": "BRAF/MEK inhibitors",
                    "plan_details": "Dabrafenib + trametinib",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Targeted option"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "NTRK fusion-positive",
                    "plan_name": "TRK inhibitors",
                    "plan_details": "Larotrectinib/entrectinib",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Targeted option"
                }
            ]
        },
        {
            "staging_criteria": "Pediatric Diffuse High-Grade Gliomas (pHGG): Location (pontine vs. non-pontine), H3 K27 status, resection extent",
            "risk_group": "Age ≥3 years, H3 K27-altered pontine",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Pontine tumors",
                    "plan_name": "Radiation monotherapy",
                    "plan_details": "Radiation Therapy alone (50.4–54 Gy)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard regimen"
                }
            ]
        },
        {
            "staging_criteria": "Pediatric Diffuse High-Grade Gliomas (pHGG): Location (pontine vs. non-pontine), H3 K27 status, resection extent",
            "risk_group": "Age <3 years",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Infants",
                    "plan_name": "Chemotherapy delay",
                    "plan_details": "Cyclophosphamide/vincristine/cisplatin/etoposide or vincristine/carboplatin/temozolomide to delay RT",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard regimen"
                }
            ]
        },
        {
            "staging_criteria": "Pediatric Diffuse High-Grade Gliomas (pHGG) recurrent/progressive",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "treatment_line": "Recurrent treatment",
                    "patient_subgroup": "Hypermutated tumors",
                    "plan_name": "Checkpoint inhibitors",
                    "plan_details": "Nivolumab/pembrolizumab",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Biomarker-driven option"
                },
                {
                    "treatment_line": "Recurrent treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Palliative chemotherapy",
                    "plan_details": "Oral etoposide (21 days/28-day cycle) or bevacizumab or lomustine/carmustine",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Palliative option"
                }
            ]
        },
        {
            "staging_criteria": "Pediatric Medulloblastoma (PMB): Metastatic status, residual disease, molecular subgroup",
            "risk_group": "Low/Average Risk (M0, GTR/NTR ≤1.5 cm², WNT/SHH/Group 4)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Risk-adapted chemoradiation",
                    "plan_details": "CSI 23.4 Gy + tumor bed boost 30.6 Gy (total 54 Gy) + chemotherapy (vincristine during RT → cisplatin/lomustine/vincristine)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Pediatric Medulloblastoma (PMB): Metastatic status, residual disease, molecular subgroup",
            "risk_group": "High/Very High Risk (M+, residual >1.5 cm², MYC amp, TP53 mut, Group 3)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "General",
                    "plan_name": "Intensified chemoradiation",
                    "plan_details": "CSI 36 Gy + boost 18–19.8 Gy (total 54–55.8 Gy) + carboplatin + chemotherapy (cisplatin/cyclophosphamide/vincristine)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard regimen"
                },
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Group 3 tumors",
                    "plan_name": "Carboplatin-enhanced RT",
                    "plan_details": "Carboplatin during radiation therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Subgroup-specific"
                }
            ]
        },
        {
            "staging_criteria": "Pediatric Medulloblastoma (PMB) recurrent/progressive",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "treatment_line": "Recurrent treatment",
                    "patient_subgroup": "Local recurrence",
                    "plan_name": "Re-resection ± RT",
                    "plan_details": "Surgical re-resection ± focal reirradiation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Local therapy"
                },
                {
                    "treatment_line": "Recurrent treatment",
                    "patient_subgroup": "Disseminated disease",
                    "plan_name": "Systemic therapy",
                    "plan_details": "Temozolomide + irinotecan ± bevacizumab or MEMMAT metronomic therapy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Palliative option"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "H3 K27-altered: Diagnostic for grade 4 diffuse midline glioma; poor prognosis; guides RT-only approach for pontine tumors",
            "BRAF V600E: Predicts sensitivity to BRAF/MEK inhibitors (dabrafenib/trametinib)",
            "NTRK fusions: Predict response to TRK inhibitors (larotrectinib/entrectinib)",
            "Hypermutation (TMB-high): Predicts response to immune checkpoint inhibitors (nivolumab/pembrolizumab)",
            "WNT subgroup (CTNNB1): Favorable prognosis; allows reduced radiation dosing",
            "SHH subgroup (TP53-wildtype): Intermediate prognosis; standard therapy",
            "SHH subgroup (TP53-mutant): Poor prognosis; requires high-risk protocols",
            "Group 3 (MYC amp): High metastatic risk; poor prognosis; mandates intensified therapy",
            "Group 4 (MYCN amp): Intermediate prognosis"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：儿童中枢神经系统肿瘤.txt"
}